Erbitux Addition to Chemotherapy Regimen Can Make Inoperable Disease Operable
Intermittent Androgen Deprivation Therapy Not Equal to Continuous Treatment, Study Finds
Three Organizations Publish Guideline For Biomarker Testing for Targeted Therapies
Avoiding Mediastinal Radiation Can Improve Patient Outcomes
Obese Men With Benign Biopsy At High Risk for Prostate Cancer
Ibrutinib Shows Disease Control In Elderly, High-Risk CLL Patients
Study Finds That CTC Was Used Correctly In Medicare Patients
ASCO Draft Recommendations Define Meaningful Trial Outcomes
Phase II Study Cohort Fails To Overcome Erlotinib Resistance
Alcohol Consumption Does Not Impact Survival of Breast Cancer
Study: Blood Test More Accurate Than Traditional Tumor Biopsy
European Treatment Regimen Less Toxic Than American Method
Study Finds Nearly Two-Thirds Of Children Return to Hospital Following Stem Cell Transplant
NCI CTEP Approved Trials For the Month of April
FDA Breakthrough Designation Granted to Pfizer’s Palbociclib
Trending Stories
- She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research
- Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology - HHS seems poised to exert control over USPSTF
Ransohoff: The task force is the pinnacle of evidence-based medicine - First-ever financial toxicity tumor board aims to change the standard of care
Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI - Imaging’s ride to the bottom in clinical trials—and why it matters now
- In The Headlines: What happens when you apply a tumor board model to financial toxicity?
